835 research outputs found
Effects of Force Modulation on Large Muscles during Human Cycling
Voluntary force modulation is defined as the ability to tune the application of force during motion. However, the mechanisms behind this modulation are not yet fully understood. In this study, we examine muscle activity under various resistance levels at a fixed cycling speed. The main goal of this research is to identify significant changes in muscle activation related to the real-time tuning of muscle force. This work revealed significant motor adaptations of the main muscles utilized in cycling as well as positive associations between the force level and the temporal and spatial inter-cycle stability in the distribution of sEMG activity. From these results, relevant biomarkers of motor adaptation could be extracted for application in clinical rehabilitation to increase the efficacy of physical therapy.This research was funded by Generalitat Valenciana (grant number GV/2019/025) and the Kakenhi National Japanese Grant for Early-Career Scientists (grant number 18K18431)
Quantification of Extent of Muscle-skin Shifting by Traversal sEMG Analysis Using High-density sEMG Sensor
Averaging electromyographic activity prior to muscle synergy computation is a common method employed to compensate for the inter-repetition variability usually associated with this kind of physiological recording. Capturing muscle synergies requires the preservation of accurate temporal and spatial information for muscle activity. The natural variation in electromyography data across consecutive repetitions of the same task raises several related challenges that make averaging a non-trivial process. Duration and triggering times of muscle activity generally vary across different repetitions of the same task. Therefore, it is necessary to define a robust methodology to segment and average muscle activity that deals with these issues. Emerging from this need, the present work proposes a standard protocol for segmenting and averaging muscle activations from periodic motions in a way that accurately preserves the temporal and spatial information contained in the original data and enables the isolation of a single averaged motion period. This protocol has been validated with muscle activity data recorded from 15 participants performing elbow flexion/extension motions, a series of actions driven by well-established muscle synergies. Using the averaged data, muscle synergies were computed, permitting their behavior to be compared with previous results related to the evaluated task. The comparison between the method proposed and a widely used methodology based on motion flags, shown the benefits of our system maintaining the consistency of muscle activation timings and synergie
Envejecimiento de la población trabajadora, adaptación del puesto de trabajo y despido por razones de salud
en este trabajo se analizará el envejecimiento de la población trabajadora y sus repercusiones sociales y económicas en las empresas. Se centra en la población activa entre 55 y 64 años. También consideramos la posibilidad de que estos trabajadores estén dentro del grupo de trabajadores especialmente sensibles por sus características psicofísicas y la adaptación al puesto de trabajo que esto conlleve, al igual de que la posibilidad de que las empresas obtén por su despido por razones absentismo hospitalario o incapacidad sobrevenid
Diachronism in the late Neoproterozoic–Cambrian arc-rift transition of North Gondwana: A comparison of Morocco and the Iberian Ossa-Morena Zone
Nanostructured porous silicon micropatterns as a tool for substrate-conditioned cell research
The localized irradiation of Si allows a precise patterning at the microscale of nanostructured materials such as porous silicon (PS). PS patterns with precisely defined geometries can be fabricated using ion stopping masks. The nanoscale textured micropatterns were used to explore their influence as microenvironments for human mesenchymal stem cells (hMSCs). In fact, the change of photoluminescence emission from PS upon aging in physiological solution suggests the intense formation of silanol surface groups, which may play a relevant role in ulterior cell adhesion. The experimental results show that hMSCs are sensitive to the surface micropatterns. In this regard, preliminary β-catenin labeling studies reveal the formation of cell to cell interaction structures, while microtubule orientation is strongly influenced by the selective adhesion conditions. Relevantly, Ki-67 assays support a proliferative state of hMSCs on such nanostructured micropatterns comparable to that of standard cell culture platforms, which reinforce the candidature of porous silicon micropatterns to become a conditioning structure for in vitro culture of hMSCsThe authors gratefully acknowledge the financial support from MICINN under research project MAT2008-06858-C02-01/NAN and Comunidad de Madrid (Spain) under Project Microseres. Technical support from L García Pelayo is greatly appreciate
Cardiac dysfunction and remodeling regulated by anti-angiogenic environment in patients with preeclampsia : the ANGIOCOR prospective cohort study protocol
Background: Cardiovascular diseases (CVD) are cause of increased morbidity and mortality in spite of advances for diagnosis and treatment. Changes during pregnancy affect importantly the maternal CV system. Pregnant women that develop preeclampsia (PE) have higher risk (up to 4 times) of clinical CVD in the short- and long-term. Predominance of an anti-angiogenic environment during pregnancy is known as main cause of PE, but its relationship with CV complications is still under research. We hypothesize that angiogenic factors are associated to maternal cardiac dysfunction/remodeling and that these may be detected by new cardiac biomarkers and maternal echocardiography. Methods: Prospective cohort study of pregnant women with high-risk of PE in first trimester screening, established diagnosis of PE during gestation, and healthy pregnant women (total intended sample size n = 440). Placental biochemical and biophysical cardiovascular markers will be assessed in the first and third trimesters of pregnancy, along with maternal echocardiographic parameters. Fetal cardiac function at third trimester of pregnancy will be also evaluated and correlated with maternal variables. Maternal cardiac function assessment will be determined 12 months after delivery, and correlation with CV and PE risk variables obtained during pregnancy will be evaluated. Discussion: The study will contribute to characterize the relationship between anti-angiogenic environment and maternal CV dysfunction/remodeling, during and after pregnancy, as well as its impact on future CVD risk in patients with PE. The ultimate goal is to improve CV health of women with high-risk or previous PE, and thus, reduce the burden of the disease. Trial registration: NCT04162236
Engineering of silicon surfaces at the micro- and nanoscales for cell adhesion and migration control
The engineering of surface patterns is a powerful tool for analyzing cellular communication factors involved in the processes of adhesion, migration, and expansion, which can have a notable impact on therapeutic applications including tissue engineering. In this regard, the main objective of this research was to fabricate patterned and textured surfaces at micron- and nanoscale levels, respectively, with very different chemical and topographic characteristics to control cell–substrate interactions. For this task, one-dimensional (1-D) and two-dimensional (2-D) patterns combining silicon and nanostructured porous silicon were engineered by ion beam irradiation and subsequent electrochemical etch. The experimental results show that under the influence of chemical and morphological stimuli, human mesenchymal stem cells polarize and move directionally toward or away from the particular stimulus. Furthermore, a computational model was developed aiming at understanding cell behavior by reproducing the surface distribution and migration of human mesenchymal stem cells observed experimentally
LIBROS BLANCOS CSIC 2030. DESAFIOS CIENTIFICOS EN TEMÁTICAS ESTRATÉGICAS.JORNADA DE PRESENTACIÓN EN EL CONTEXTO DEL PLAN ESTRATÉGICO CSIC 2025
Role of targeted therapies in rheumatic patients on COVID-19 outcomes: Results from the COVIDSER study
Objectives To analyse the effect of targeted therapies, either biological (b) disease-modifying antirheumatic drugs (DMARDs), targeted synthetic (ts) DMARDs and other factors (demographics, comorbidities or COVID-19 symptoms) on the risk of COVID-19 related hospitalisation in patients with inflammatory rheumatic diseases. Methods The COVIDSER study is an observational cohort including 7782 patients with inflammatory rheumatic diseases. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Antirheumatic medication taken immediately prior to infection, demographic characteristics, rheumatic disease diagnosis, comorbidities and COVID-19 symptoms were analysed. Results A total of 426 cases of symptomatic COVID-19 from 1 March 2020 to 13 April 2021 were included in the analyses: 106 (24.9%) were hospitalised and 19 (4.4%) died. In multivariate-adjusted models, bDMARDs and tsDMARDs in combination were not associated with hospitalisation compared with conventional synthetic DMARDs (OR 0.55, 95% CI 0.24 to 1.25 of b/tsDMARDs, p=0.15). Tumour necrosis factor inhibitors (TNF-i) were associated with a reduced likelihood of hospitalisation (OR 0.32, 95% CI 0.12 to 0.82, p=0.018), whereas rituximab showed a tendency to an increased risk of hospitalisation (OR 4.85, 95% CI 0.86 to 27.2). Glucocorticoid use was not associated with hospitalisation (OR 1.69, 95% CI 0.81 to 3.55). A mix of sociodemographic factors, comorbidities and COVID-19 symptoms contribute to patients'' hospitalisation. Conclusions The use of targeted therapies as a group is not associated with COVID-19 severity, except for rituximab, which shows a trend towards an increased risk of hospitalisation, while TNF-i was associated with decreased odds of hospitalisation in patients with rheumatic disease. Other factors like age, male gender, comorbidities and COVID-19 symptoms do play a role.
Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study
Objectives: To analyse the effect of targeted therapies, either biological (b) disease-modifying antirheumatic drugs (DMARDs), targeted synthetic (ts) DMARDs and other factors (demographics, comorbidities or COVID-19 symptoms) on the risk of COVID-19 related hospitalisation in patients with inflammatory rheumatic diseases.
Methods: The COVIDSER study is an observational cohort including 7782 patients with inflammatory rheumatic diseases. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Antirheumatic medication taken immediately prior to infection, demographic characteristics, rheumatic disease diagnosis, comorbidities and COVID-19 symptoms were analysed.
Results: A total of 426 cases of symptomatic COVID-19 from 1 March 2020 to 13 April 2021 were included in the analyses: 106 (24.9%) were hospitalised and 19 (4.4%) died. In multivariate-adjusted models, bDMARDs and tsDMARDs in combination were not associated with hospitalisation compared with conventional synthetic DMARDs (OR 0.55, 95% CI 0.24 to 1.25 of b/tsDMARDs, p=0.15). Tumour necrosis factor inhibitors (TNF-i) were associated with a reduced likelihood of hospitalisation (OR 0.32, 95% CI 0.12 to 0.82, p=0.018), whereas rituximab showed a tendency to an increased risk of hospitalisation (OR 4.85, 95% CI 0.86 to 27.2). Glucocorticoid use was not associated with hospitalisation (OR 1.69, 95% CI 0.81 to 3.55). A mix of sociodemographic factors, comorbidities and COVID-19 symptoms contribute to patients' hospitalisation.
Conclusions: The use of targeted therapies as a group is not associated with COVID-19 severity, except for rituximab, which shows a trend towards an increased risk of hospitalisation, while TNF-i was associated with decreased odds of hospitalisation in patients with rheumatic disease. Other factors like age, male gender, comorbidities and COVID-19 symptoms do play a role.This Project has been financed by Bristol-Myers Squibb, Galapagos Biopharma Spain SLU, Gebro Pharma, Roche Farma and Sanofi Aventis
- …